EX-99..1
5
exhibit4.htm
EX-99..1
EX-99..1
FOR IMMEDIATE RELEASE
GUILFORD PHARAMCEUTICALS COMPLETES
SALE AND LEASEBACK AND RECEIVES $19.4 MILLION IN NET PROCEEDS
BALTIMORE, MD
, December 17, 2004 - Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) today announced
that it has completed a sale and leaseback of its facilities in Baltimore, Maryland with BioMed
Realty Trust, Inc., a real estate investment trust focused on acquiring, owning, leasing and
developing laboratory and office space for life science, biotechnology and pharmaceutical
companies. The net proceeds of this transaction to Guilford were $19.4 million. In connection
with this transaction, Guilford has entered into a long-term lease with BioMed for the facilities.
Guilford intends to use the proceeds for general corporate purposes, including providing additional
working capital to support its development pipeline and the continued advancement of the Company's
AQUAVAN® Injection development program, currently in Phase III clinical testing.
About Guilford
Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and
commercialization of proprietary drugs that target the hospital and neurology markets. Presently,
Guilford markets two commercial products, GLIADEL
®
Wafer (polifeprosan 20 with
carmustine implant), for the treatment of certain types of brain tumor in combination with
radiation and surgery, and AGGRASTAT
®
Injection (tirofiban hydrochloride), a
glycoprotein GP IIb/IIIa receptor antagonist, for the treatment of acute coronary syndrome (ACS).
Guilford's product pipeline includes AQUAVAN
®
Injection, an investigational
sedative/anesthetic drug, and drugs for treating peripheral nerve injury. For full prescribing
information, please visit
www.guilfordpharm.com
under Products / Marketed Products.
###
Contact:
Guilford Pharmaceuticals Inc.
Stacey Jurchison 410.631.5022
jurchisons@guilfordpharm.com
Internet addresses: www.guilfordpharm.com

EX - 99 . . 1 5 exhibit4 . htm EX - 99 . . 1 EX - 99 . . 1 FOR IMMEDIATE RELEASE GUILFORD PHARAMCEUTICALS COMPLETES SALE AND LEASEBACK AND RECEIVES $ 19.4 MILLION IN NET PROCEEDS BALTIMORE , MD , December 17 , 2004 - Guilford Pharmaceuticals Inc . ( Nasdaq : GLFD ) today announced that it has completed a sale and leaseback of its facilities in Baltimore , Maryland with BioMed Realty Trust , Inc . , a real estate investment trust focused on acquiring , owning , leasing and developing laboratory and office space for life science , biotechnology and pharmaceutical companies . The net proceeds of this transaction to Guilford were $ 19.4 million . In connection with this transaction , Guilford has entered into a long - term lease with BioMed for the facilities . Guilford intends to use the proceeds for general corporate purposes , including providing additional working capital to support its development pipeline and the continued advancement of the Company 's AQUAVAN ® Injection development program , currently in Phase III clinical testing . About Guilford Guilford Pharmaceuticals Inc . is a pharmaceutical company engaged in the research , development and commercialization of proprietary drugs that target the hospital and neurology markets . Presently , Guilford markets two commercial products , GLIADEL ® Wafer ( polifeprosan 20 with carmustine implant ) , for the treatment of certain types of brain tumor in combination with radiation and surgery , and AGGRASTAT ® Injection ( tirofiban hydrochloride ) , a glycoprotein GP IIb / IIIa receptor antagonist , for the treatment of acute coronary syndrome ( ACS ) . Guilford 's product pipeline includes AQUAVAN ® Injection , an investigational sedative / anesthetic drug , and drugs for treating peripheral nerve injury . For full prescribing information , please visit www.guilfordpharm.com under Products / Marketed Products . # # # Contact : Guilford Pharmaceuticals Inc . Stacey Jurchison 410 . 631 . 5022 jurchisons@guilfordpharm.com Internet addresses : www.guilfordpharm.com
O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O